Navigation Links
Amicus Therapeutics Announces First Quarter 2008 Financial Results
Date:5/13/2008

.

Other Chaperone Programs:

Amicus is accelerating its investment in research and development to assess the potential for using pharmacological chaperones to treat a broader range of human genetic diseases beyond lysosomal storage diseases. As part of this effort, Amicus continues to conduct preclinical studies in Parkinson's disease, funded in part by a grant from the Michael J. Fox Foundation. In addition to the work in Parkinson's, Amicus is investing in new research aimed at evaluating disease targets for other neurodegenerative disorders and metabolic disorders.

Shire Collaboration:

In November 2007, Amicus entered into a strategic collaboration with Shire Human Genetic Therapies (HGT), a business unit of Shire plc, to jointly develop Amicus' three lead pharmacological chaperone compounds for lysosomal storage disorders, Amigal, Plicera and AT2220. In this collaboration valued at up to $440 million including an up front payment and success based clinical and sales milestones and excluding royalties and cost sharing, Shire also reimburses worldwide development costs on a 50/50 basis. Under the agreement, Shire received rights to commercialize these products outside of the United States. Amicus retains all rights to commercialize these products in the United States. Amicus will lead development operations through the end of Phase 2 clinical trials. The companies will then share responsibility for Phase 3 clinical trial development leveraging Shire's significant ex-US regulatory and clinical experience as well as its commercial infrastructure.

Additional Financial Results & Notes

On a reported basis, the net loss attributable to common stockholders for the three months ended March 31, 2008, was $7.7 million as compared to $9.7 million for the same period in 2007. On a non-GAAP basis, the net loss for the three months ended March 31, 2008, was $6.4 million as compared to $8.9 million and the same period in 2007.

Amic
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... NY (PRWEB) June 02, 2015 ... on health care, Jack Uldrich has been selected ... in New York today. He will deliver his ... , Uldrich has delivered presentations to the American ... of Audiology and Neurology, Alcetel-Lucent/Verizon Forum on Wireless ...
(Date:6/1/2015)... and RARITAN, N.J. , June ... (Janssen) announced data from the Phase 3 multicenter ... progression-free survival (PFS) with trabectedin (YONDELIS ® ) ... (LPS) or leiomyosarcoma (LMS) previously treated with an ... SAR3007 is the largest randomized Phase 3 study ...
(Date:6/1/2015)... , June 1, 2015  Novartis is highlighting ... of CTL019, an investigational chimeric antigen receptor (CAR) ... the treatment of specific types of hard-to-treat non-Hodgkin ... the University of Pennsylvania,s Perelman School of Medicine ... diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma ...
(Date:6/1/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/9kv3rl/global ... "Global Bioinformatics Market 2015-2019" report to their ... bioinformatics market to grow at a CAGR of ... a field of science that includes computational analysis ... in DNA form and protein sequences in various ...
Breaking Biology Technology:Futurist Jack Uldrich to Address the Future of Pharmaceuticals 2Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 2Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 3Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 4Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 5Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 6Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 2Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 3Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 4Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 5Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 6Global Bioinformatics Market 2015-2019 - Rapid Developments in Molecular Diagnostics 2Global Bioinformatics Market 2015-2019 - Rapid Developments in Molecular Diagnostics 3
... Nov. 24 Terumo Heart, Inc. is pleased to,announce ... Chief Executive,Officer (C.E.O.) and President, effective immediately. "With its ... leadership role in,the future treatment of heart failure. I ... DuraHeart U.S. Pivotal trials in up to 40 clinical ...
... LAKE, N.J., Nov. 24 Eisai Inc., in ... of the,C.A.R.E. (Commitment to Alzheimer,s. Recognition of Excellence.) ... pharmacist who has been,nominated by a person with ... her,exceptional impact on the lives of those fighting ...
... companies serving biotech/pharma industry to find new business opportunities and ... ... (PRWEB) November 24, 2008 -- In response to challenging economic ... its PharmSource Lead Sheet, a weekly web-based service that reports ...
Cached Biology Technology:Terumo Heart Announces Appointment of William Pinon to Chief Executive Officer and President 2Eisai Inc. and the Alzheimer's Association Announce the Winner of the C.A.R.E. Pharmacy Award 2Eisai Inc. and the Alzheimer's Association Announce the Winner of the C.A.R.E. Pharmacy Award 3PharmSource Introduces Proprietary Resource for Identifying New Business Opportunities in Bio/Pharma 2
(Date:5/5/2015)... Conn. , May 5, 2015, NXT-ID, Inc. ... authentication company focused on the growing mobile commerce market, reminds ... Company,s Chief Technology Officer, is presenting  at CARTES SECURE CONNEXIONS ... May 5-7, 2015. The three-day conference is ... David is speaking in is themed Global Fraud: Where ...
(Date:4/21/2015)... -- High crime rate, increasing government ... control systems market in Saudi Arabia ... report by TechSci Research " Saudi Arabia Access Control Systems Market ... market in Saudi Arabia is ... systems market in the Kingdom is growing at a ...
(Date:4/14/2015)... YORK , April 14, 2015  HYPR ... IDentity Online (FIDO ® ) Alliance tm , ... specifications. FIDO members commit to share technology and ... methods that are interoperable, more secure and private, ... enable biometric identity verification that protects sensitive user ...
Breaking Biology News(10 mins):NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 2Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3
... In a new study published in the August 16th ... Medical Center identified a molecular mechanism that guarantees that new ... proper abundance. "We have known for a long time ... and that in some places of our bodies this branching ...
... CORVALLIS, Ore. A recent study suggests that parasites ... have more profound impacts on fish health than has been ... which habitat and land use changes cause salmon mortality. ... is important, the research found, but their numbers that can ...
... TORONTO, August 15, 2011 A study out of ... be good for you. Published today in the journal ... that obese people who are otherwise healthy live just as ... die of cardiovascular causes. "Our findings challenge the ...
Cached Biology News:Parasite loads an underlying cause of salmon mortality, linked to land use changes 2Fat and healthy? York U study finds slim isn't always superior 2
... Dithiothreitol, 1 g. High ... convenient sample preparation that give ... disrupt cells and tissues.Clean up ... sample volumes. Accurately quantitate protein ...
... Cary 50 Microplate Reader accessory ... per analysis by extending the ... award-winning Cary 50 instruments. Use ... 384 samples in microlitre volumes, ...
GOAT ANTI CARICA PAPAYA PAPAIN...
IMAGEQUANT 400 WKSTN, 1 EA. Category: ImageQuant CCD Imagers....
Biology Products: